Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Raphael Darcy"'
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e66413 (2013)
Optimising non-viral vectors for neuronal siRNA delivery presents a significant challenge. Here, we investigate a co-formulation, consisting of two amphiphilic cyclodextrins (CDs), one cationic and the other PEGylated, which were blended together for
Externí odkaz:
https://doaj.org/article/ebe98ab8d4914a6c8408c6186a4fc090
Autor:
Pierre-Andre Cazade, Irina Dorin, Caitriona M. O'Driscoll, Michael F. Cronin, Raghvendra Pratap Singh, Damien Thompson, Tania Hidalgo, Raphael Darcy
Publikováno v:
Molecular Pharmaceutics
peer-reviewed The full text of this article will not be available in ULIR until the embargo expires on the 5/02/2019 Functionalized cyclodextrin molecules assemble into a wide variety of superstructures in solution, which are of interest for drug del
Autor:
Raphael Darcy, Jianfeng Guo, Irene Mencía Castaño, Fergal J. O’ Brien, Rosanne M. Raftery, Caitriona M. O’ Driscoll, Caroline M. Curtin, Matt Gooding, Kathleen A. Fitzgerald
Publikováno v:
International Journal of Pharmaceutics. 511:1058-1069
siRNA has emerged as a potential therapeutic for the treatment of prostate cancer but effective delivery remains a major barrier to its clinical application. This study aimed to develop and characterise a 3D in vitro co-culture model to simulate pros
Autor:
Matt Gooding, Raphael Darcy, Caitriona M. O'Driscoll, James C. Evans, Meenakshi Malhotra, Kathleen A. Fitzgerald, Florence Sallas
Publikováno v:
International Journal of Pharmaceutics. 499:131-145
Prostate cancer is a leading cause of cancer-related death in men and RNA interference (RNAi) has emerged as a potential therapeutic option. However, the absence of a safe and specific delivery vector remains a major obstacle to the clinical applicat
Autor:
Raphael Darcy, Caitriona M. O'Driscoll, Bruno M.D.C. Godinho, David J. McCarthy, Meenakshi Malhotra, Matt Gooding, John F. Cryan
Publikováno v:
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
In man brain cancer is an aggressive, malignant form of tumour, it is highly infiltrative in nature, is associated with cellular heterogeneity and affects cerebral hemispheres of the brain. Current drug therapies are inadequate and an unmet clinical
Autor:
James C. Evans, Meenakshi Malhotra, Daniel O’Driscoll, Caitriona M. O'Driscoll, Raphael Darcy, Matt Gooding
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 114
Functional siRNAs (luciferase and PLK1) have been conjugated to β-cyclodextrin and the ability of the conjugates to retain gene knockdown activity has been assessed by delivery to cancer cell lines using various formulations. Initially two formulati
Autor:
Colleen C. Nelson, Katrina Sweeney, Meenakshi Malhotra, Brett G. Hollier, Raphael Darcy, Caitriona M. O'Driscoll, James C. Evans
Publikováno v:
International journal of pharmaceutics. 532(1)
The main barrier to the development of an effective RNA interference (RNAi) therapy is the lack of a suitable delivery vector. Modified cyclodextrins have emerged in recent years for the delivery of siRNA. In the present study, a folate-targeted amph
Autor:
Caitriona M. O'Driscoll, Jianfeng Guo, Thomas G. Cotter, Eileen G. Russell, Sharon L. McKenna, Raphael Darcy, Mary R. Cahill
Publikováno v:
Molecular pharmaceutics. 14(3)
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults and is associated with high relapse rates. It is known that leukemia stem cells (LSCs), a very small subpopulation of the total number of leukemic cells, maintain the le
Autor:
Caitriona M. O'Driscoll, Meenakshi Malhotra, Michael F. Cronin, Caroline M. Curtin, Jianfeng Guo, James C. Evans, Raphael Darcy, Fergal J. O'Brien, Kathleen A. Fitzgerald
Publikováno v:
Molecular pharmaceutics. 14(1)
In recent years, RNA interference (RNAi) has emerged as a potential therapeutic offering the opportunity to treat a wide range of diseases, including prostate cancer. Modified cyclodextrins have emerged as effective gene delivery vectors in a range o
Autor:
Bruno M.D.C. Godinho, Julien Ogier, Caitriona M. O'Driscoll, Aoife Quinlan, Raphael Darcy, Brendan T. Griffin, John F. Cryan
Publikováno v:
International Journal of Pharmaceutics. 473:105-112
Silencing disease-related genes in the central nervous system (CNS) using short interfering RNA (siRNA) holds great promise for treating neurological disorders. Yet, delivery of RNAi therapeutics to the brain poses major challenges to non-viral syste